


Branded biologics respond to biosimilar competition by lowering their prices

CASE STUDY

Biosimilar competition for Remicade, a blockbuster biologic for the treatment of rheumatoid arthritis, helped drive the price of the branded biologic below that of biosimilar entrants

- Remicade
- Inflectra (Biosimilar)
- Renflexis (Biosimilar)
- Remicade Market Share



Note: ASP values published by CMS lag behind the market ASP by two quarters (e.g. ASP guidelines published in July 2018 reflect the actual sales 01-2018).
Source: CMS Reported ASP/100 mg vial.